{
  "Disease": [
    {"role": "user", "content": "Please identify the \"Disease\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Disease\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| fibrinolytic disorders |\n| disseminated intravascular coagulation |\n| consumption coagulopathies |"},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Disease\" and present the valid entities as a Markdown table with one column \"Disease\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| fibrinolytic disorders |\n| disseminated intravascular coagulation |\n| consumption coagulopathies |\n\nThese entities are clearly referred to as diseases in the paragraph. \"Fibrinolytic disorders\" is a condition characterized by impaired fibrinolysis, \"disseminated intravascular coagulation\" is a serious condition in which blood clots form throughout the body, and \"consumption coagulopathies\" is a group of conditions characterized by excessive consumption of clotting factors."}
  ],
  "Chemical": [
    {"role": "user", "content": "Please identify the \"Chemical\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Chemical\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| fibrin |\n| EACA (Epsilon-Aminocaproic Acid) |\n\nThe paragraph mentions \"fibrin thrombi\" and \"EACA (Epsilon-Aminocaproic Acid)\" as chemical entities."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Chemical\" and present the valid entities as a Markdown table with one column \"Chemical\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| fibrin |\n| Epsilon-Aminocaproic Acid (EACA) |\n\nThe paragraph mentions \"fibrin thrombi\" and \"Epsilon-Aminocaproic Acid (EACA)\" as chemical entities. \"Fibrin\" refers to a protein that forms a clot to stop bleeding, while \"Epsilon-Aminocaproic Acid (EACA)\" is a medication used to prevent the breakdown of blood clots."}
  ]
}